Sector News

AstraZeneca CEO: We want a ‘strong, science-led FDA’

February 2, 2017
Life sciences

The chief of AstraZeneca Pascal Soriot said during the Big Pharma’s financials this morning that he wants a “science-led FDA” as President Donald Trump’s administration looks to slash regulations, and potentially staff, from across the agency.

In the Q4 update call to journalists and analysts, Soriot said: “We actually believe in a strong, science-led FDA. We are a science-led organization that thrives to hit high scientific standards and so we would expect the FDA to be well staffed and focused also on those standards.”

But he said that there are always opportunities to “do things better” and so “we continue to engage with the FDA to do what that have done very successfully in oncology over the past few years, which is finding new pathways to accelerate approvals of new drugs or indications.

“If you look back over the past few years, quite a number of breakthroughs in cancer in oncology have been brought to patients in the U.S., and the oncology department [from the FDA] has been trailblazing from the point of view.”

He cautioned that there is a limit to “how fast we can go in doing those things well.”

This comes as Trump sat down with a number of Big Pharma chiefs earlier this week and said he was seeking to cut down on regulations at the FDA, and was also likely to, as part of a broader hiring freeze across the country for federal employees, reduce headcount at the agency in the coming years through attrition.

Trump said at the meeting: “We’re going to get rid of a tremendous number of regulations. We’re going to be cutting regulations like nobody has ever seen before. And we’re going to have tremendous protections for the people, perhaps even more protections for the people. We’re going to streamline the FDA.

“We have a fantastic person [to lead the Agency] that I think I will be naming very soon. We’re going to streamline the FDA. You’re going to get your products either approved or not approved but it’s going to be a quick process. It’s not going to take 15 years.”

This was largely backed by biopharma groups BIO and PhRMA, but was criticized by U.S. lawmakers.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach